Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Immunomodulators), By Application, By Distribution Channel, By End-use, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 2 Business Days
Cancer Immunotherapy Market Growth & Trends
The global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.
Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.
Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.
The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.
Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.
Cancer Immunotherapy Market Report Highlights
Cancer Immunotherapy Market Growth & Trends
The global cancer immunotherapy market is expected to reach USD 196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.
Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.
Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.
The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.
Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.
Cancer Immunotherapy Market Report Highlights
- Monoclonal antibodies segment held the largest market share in 2021 owing to rising investments in the R&D of monoclonal antibodies
- By product, the oncolytic viral therapies &cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
- Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
- The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
- The hospitals & clinics segment led the market in 2021 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
- Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
- Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 CANCER IMMUNOTHERAPY MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing prevalence of cancer
3.2.1.2 Growing R&D activities by pharmaceutical companies
3.2.1.3 Technological advancements and introduction of novel drugs
3.2.2 Market restraint analysis
3.2.2.1 Risk of side effects associated with the treatment
3.2.2.2 High cost of therapy and unfavourable reimbursement scenario
3.3 Penetration & Growth Prospect Mapping
3.4 Cancer Immunotherapy: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
CHAPTER 4 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Definition and Scope
4.2 Product Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Cancer Immunotherapy Market, by Product, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Monoclonal antibodies
4.5.1.1 Monoclonal antibodies market, 2018 - 2030 (USD Million)
4.5.2 Immunomodulators
4.5.2.1 Immunomodulators market, 2018 - 2030 (USD Million)
4.5.3 Oncolytic viral therapies and cancer vaccines
4.5.3.1 Oncolytic viral therapies and cancer vaccines market, 2018 - 2030 (USD Million)
CHAPTER 5 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY APPLICATION 2018 - 2030 (USD MILLION)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Cancer Immunotherapy Market, by Application, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Lung cancer
5.5.1.1 Lung cancer market, 2018 - 2030 (USD Million)
5.5.2 Breast cancer
5.5.2.1 Breast cancer market, 2018 - 2030 (USD Million)
5.5.3 Colorectal cancer
5.5.3.1 Colorectal cancer market, 2018 - 2030 (USD Million)
5.5.4 Melanoma
5.5.4.1 Melanoma market, 2018 - 2030 (USD Million)
5.5.5 Prostate cancer
5.5.5.1 Prostate cancer market, 2018 - 2030 (USD Million)
5.5.6 Head and neck cancer
5.5.6.1 Head and neck cancer market, 2018 - 2030 (USD Million)
5.5.7 Ovarian cancer
5.5.7.1 Ovarian cancer market, 2018 - 2030 (USD Million)
5.5.8 Pancreatic cancer
5.5.8.1 Pancreatic cancer market, 2018 - 2030 (USD Million)
5.5.9 Others
5.5.9.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
6.1 Definition and Scope
6.2 Distribution Channel Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Cancer Immunotherapy Market, by Distribution Channel, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Hospital Pharmacy
6.5.1.1 Hospital pharmacy market, 2018 - 2030 (USD Million)
6.5.2 Retail Pharmacy
6.5.2.1 Retail pharmacy market, 2018 - 2030 (USD Million)
6.5.3 Online Pharmacy
6.5.3.1 Online pharmacy market, 2018 - 2030 (USD Million)
CHAPTER 7 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY END-USE, 2018 - 2030 (USD MILLION)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Cancer Immunotherapy Market, by End-use, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Hospitals & Clinics
7.5.1.1 Hospital & clinics market, 2018 - 2030 (USD Million)
7.5.2 Cancer Research Centers
7.5.2.1 Cancer research centers market, 2018 - 2030 (USD Million)
7.5.3 Others
7.5.3.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 8 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2021 & 2030
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 SWOT Analysis
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 Middle East and Africa
8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
8.6.1 North America
8.6.1.1 North America cancer immunotherapy market, 2018-2030 (USD Million)
8.6.1.2 U.S.
8.6.1.2.1 U.S. cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.1.3 Canada
8.6.1.3.1 Canada cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2 Europe
8.6.2.1 Europe cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.2 UK
8.6.2.2.1 UK cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.3 Germany
8.6.2.3.1 Germany cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.4 Spain
8.6.2.4.1 Spain cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.5 France
8.6.2.5.1 France cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.6 Italy
8.6.2.6.1 Italy cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3 Asia Pacific
8.6.3.1 Asia Pacific cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.2 Japan
8.6.3.2.1 Japan cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.3 China
8.6.3.3.1 China cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.4 India
8.6.3.4.1 India cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.5 South Korea
8.6.3.5.1 South Korea cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.6 Australia
8.6.3.6.1 Australia cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4 Latin America
8.6.4.1 Latin America cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.2 Brazil
8.6.4.2.1 Brazil cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.3 Mexico
8.6.4.3.1 Mexico cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.4 Argentina
8.6.4.4.1 Argentina cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5 MEA
8.6.5.1 MEA cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.2 South Africa
8.6.5.2.1 South Africa cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.3 Saudi Arabia
8.6.5.3.1 Saudi Arabia cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.4 UAE
8.6.5.4.1 UAE cancer immunotherapy market, 2018 - 2030 (USD Million)
CHAPTER 9 CANCER IMMUNOTHERAPY MARKET - COMPETITIVE ANALYSIS
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.1.1 Ansoff matrix
9.1.2 Heat map analysis
9.1.3 Major Deals and Strategic Alliances Analysis
9.1.3.1 Joint Ventures
9.1.3.2 Licensing Agreements
9.1.3.3 Product Launches
9.1.3.1 Conferences and Campaigns
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List of key distributors and channel partners
9.3.2 Key customers
9.4 Public Companies
9.4.1 Competitive Dashboard Analysis
9.4.1.1 Market Differentiators
9.5 Private Companies
9.5.1 List of key emerging companies
9.6 Company Profiles
9.6.1 AstraZeneca
9.6.1.1 Company overview
9.6.1.2 Financial performance
9.6.1.3 Product benchmarking
9.6.1.4 Strategic initiatives
9.6.2 Pfizer Inc.
9.6.2.1 Company overview
9.6.2.2 Financial performance
9.6.2.3 Product benchmarking
9.6.2.4 Strategic initiatives
9.6.3 Merck & Co., Inc
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic initiatives
9.6.4 F. Hoffmann-La Roche Ltd
9.6.4.1 Company overview
9.6.4.2 Financial performance
9.6.4.3 Product benchmarking
9.6.4.4 Strategic initiatives
9.6.5 Bristol-Myers Squibb Company
9.6.5.1 Company overview
9.6.5.2 Financial performance
9.6.5.3 Product benchmarking
9.6.5.4 Strategic initiatives
9.6.6 Genentech, Inc (Roche)
9.6.6.1 Company overview
9.6.6.2 Financial performance
9.6.6.3 Product benchmarking
9.6.6.4 Strategic initiatives
9.6.7 Novartis AG
9.6.7.1 Company overview
9.6.7.2 Financial performance
9.6.7.3 Product benchmarking
9.6.7.4 Strategic initiatives
9.6.8 Lilly
9.6.8.1 Company overview
9.6.8.2 Financial performance
9.6.8.3 Product benchmarking
9.6.8.4 Strategic initiatives
9.6.9 Johnson & Johnson Services, Inc
9.6.9.1 Company overview
9.6.9.2 Financial performance
9.6.9.3 Product benchmarking
9.6.9.4 Strategic initiatives
9.6.10 Immunocore, Ltd
9.6.10.1 Company overview
9.6.10.2 Financial performance
9.6.10.3 Product benchmarking
9.6.10.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Competitive Insights
CHAPTER 3 CANCER IMMUNOTHERAPY MARKET VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increasing prevalence of cancer
3.2.1.2 Growing R&D activities by pharmaceutical companies
3.2.1.3 Technological advancements and introduction of novel drugs
3.2.2 Market restraint analysis
3.2.2.1 Risk of side effects associated with the treatment
3.2.2.2 High cost of therapy and unfavourable reimbursement scenario
3.3 Penetration & Growth Prospect Mapping
3.4 Cancer Immunotherapy: Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
CHAPTER 4 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Definition and Scope
4.2 Product Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Cancer Immunotherapy Market, by Product, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Monoclonal antibodies
4.5.1.1 Monoclonal antibodies market, 2018 - 2030 (USD Million)
4.5.2 Immunomodulators
4.5.2.1 Immunomodulators market, 2018 - 2030 (USD Million)
4.5.3 Oncolytic viral therapies and cancer vaccines
4.5.3.1 Oncolytic viral therapies and cancer vaccines market, 2018 - 2030 (USD Million)
CHAPTER 5 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY APPLICATION 2018 - 2030 (USD MILLION)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Cancer Immunotherapy Market, by Application, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Lung cancer
5.5.1.1 Lung cancer market, 2018 - 2030 (USD Million)
5.5.2 Breast cancer
5.5.2.1 Breast cancer market, 2018 - 2030 (USD Million)
5.5.3 Colorectal cancer
5.5.3.1 Colorectal cancer market, 2018 - 2030 (USD Million)
5.5.4 Melanoma
5.5.4.1 Melanoma market, 2018 - 2030 (USD Million)
5.5.5 Prostate cancer
5.5.5.1 Prostate cancer market, 2018 - 2030 (USD Million)
5.5.6 Head and neck cancer
5.5.6.1 Head and neck cancer market, 2018 - 2030 (USD Million)
5.5.7 Ovarian cancer
5.5.7.1 Ovarian cancer market, 2018 - 2030 (USD Million)
5.5.8 Pancreatic cancer
5.5.8.1 Pancreatic cancer market, 2018 - 2030 (USD Million)
5.5.9 Others
5.5.9.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
6.1 Definition and Scope
6.2 Distribution Channel Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Cancer Immunotherapy Market, by Distribution Channel, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Hospital Pharmacy
6.5.1.1 Hospital pharmacy market, 2018 - 2030 (USD Million)
6.5.2 Retail Pharmacy
6.5.2.1 Retail pharmacy market, 2018 - 2030 (USD Million)
6.5.3 Online Pharmacy
6.5.3.1 Online pharmacy market, 2018 - 2030 (USD Million)
CHAPTER 7 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY END-USE, 2018 - 2030 (USD MILLION)
7.1 Definition and Scope
7.2 End-use Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Cancer Immunotherapy Market, by End-use, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Hospitals & Clinics
7.5.1.1 Hospital & clinics market, 2018 - 2030 (USD Million)
7.5.2 Cancer Research Centers
7.5.2.1 Cancer research centers market, 2018 - 2030 (USD Million)
7.5.3 Others
7.5.3.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 8 CANCER IMMUNOTHERAPY MARKET SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2021 & 2030
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 SWOT Analysis
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Latin America
8.5.5 Middle East and Africa
8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
8.6.1 North America
8.6.1.1 North America cancer immunotherapy market, 2018-2030 (USD Million)
8.6.1.2 U.S.
8.6.1.2.1 U.S. cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.1.3 Canada
8.6.1.3.1 Canada cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2 Europe
8.6.2.1 Europe cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.2 UK
8.6.2.2.1 UK cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.3 Germany
8.6.2.3.1 Germany cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.4 Spain
8.6.2.4.1 Spain cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.5 France
8.6.2.5.1 France cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.2.6 Italy
8.6.2.6.1 Italy cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3 Asia Pacific
8.6.3.1 Asia Pacific cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.2 Japan
8.6.3.2.1 Japan cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.3 China
8.6.3.3.1 China cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.4 India
8.6.3.4.1 India cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.5 South Korea
8.6.3.5.1 South Korea cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.3.6 Australia
8.6.3.6.1 Australia cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4 Latin America
8.6.4.1 Latin America cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.2 Brazil
8.6.4.2.1 Brazil cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.3 Mexico
8.6.4.3.1 Mexico cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.4.4 Argentina
8.6.4.4.1 Argentina cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5 MEA
8.6.5.1 MEA cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.2 South Africa
8.6.5.2.1 South Africa cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.3 Saudi Arabia
8.6.5.3.1 Saudi Arabia cancer immunotherapy market, 2018 - 2030 (USD Million)
8.6.5.4 UAE
8.6.5.4.1 UAE cancer immunotherapy market, 2018 - 2030 (USD Million)
CHAPTER 9 CANCER IMMUNOTHERAPY MARKET - COMPETITIVE ANALYSIS
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.1.1 Ansoff matrix
9.1.2 Heat map analysis
9.1.3 Major Deals and Strategic Alliances Analysis
9.1.3.1 Joint Ventures
9.1.3.2 Licensing Agreements
9.1.3.3 Product Launches
9.1.3.1 Conferences and Campaigns
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List of key distributors and channel partners
9.3.2 Key customers
9.4 Public Companies
9.4.1 Competitive Dashboard Analysis
9.4.1.1 Market Differentiators
9.5 Private Companies
9.5.1 List of key emerging companies
9.6 Company Profiles
9.6.1 AstraZeneca
9.6.1.1 Company overview
9.6.1.2 Financial performance
9.6.1.3 Product benchmarking
9.6.1.4 Strategic initiatives
9.6.2 Pfizer Inc.
9.6.2.1 Company overview
9.6.2.2 Financial performance
9.6.2.3 Product benchmarking
9.6.2.4 Strategic initiatives
9.6.3 Merck & Co., Inc
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic initiatives
9.6.4 F. Hoffmann-La Roche Ltd
9.6.4.1 Company overview
9.6.4.2 Financial performance
9.6.4.3 Product benchmarking
9.6.4.4 Strategic initiatives
9.6.5 Bristol-Myers Squibb Company
9.6.5.1 Company overview
9.6.5.2 Financial performance
9.6.5.3 Product benchmarking
9.6.5.4 Strategic initiatives
9.6.6 Genentech, Inc (Roche)
9.6.6.1 Company overview
9.6.6.2 Financial performance
9.6.6.3 Product benchmarking
9.6.6.4 Strategic initiatives
9.6.7 Novartis AG
9.6.7.1 Company overview
9.6.7.2 Financial performance
9.6.7.3 Product benchmarking
9.6.7.4 Strategic initiatives
9.6.8 Lilly
9.6.8.1 Company overview
9.6.8.2 Financial performance
9.6.8.3 Product benchmarking
9.6.8.4 Strategic initiatives
9.6.9 Johnson & Johnson Services, Inc
9.6.9.1 Company overview
9.6.9.2 Financial performance
9.6.9.3 Product benchmarking
9.6.9.4 Strategic initiatives
9.6.10 Immunocore, Ltd
9.6.10.1 Company overview
9.6.10.2 Financial performance
9.6.10.3 Product benchmarking
9.6.10.4 Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Leading market players anticipated to witness highest growth
Table 4 Global Cancer Immunotherapy Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 6 Global Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 7 Global Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Global Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 9 North America Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 10 North America Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 11 North America Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 12 North America Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 13 North America Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 14 U.S. Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 15 U.S. Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 16 U.S. Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 U.S. Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 18 Canada Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 19 Canada Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 20 Canada Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 Canada Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 22 Europe Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 23 Europe Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 24 Europe Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 25 Europe Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Europe Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 27 Germany Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 28 Germany Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 29 Germany Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Germany Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 31 UK Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 32 UK Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 33 UK Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 UK Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 35 France Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 36 France Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 37 France Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 France Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 39 Italy Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 40 Italy Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 41 Italy Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 42 Italy Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 43 Spain Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 44 Spain Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 45 Spain Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 Spain Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 52 Japan Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 53 Japan Cancer Immunotherapy Market, By Application 2018 - 2030 (USD Million)
Table 54 Japan Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Japan Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 56 China Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 58 China Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 59 China Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 60 India Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 61 India Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 62 India Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 63 India Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 64 Australia Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 65 Australia Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 66 Australia Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Australia Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 68 South Korea Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 69 South Korea Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 70 South Korea Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 71 South Korea Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 72 Latin America Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 73 Latin America Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 74 Latin America Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 75 Latin America Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Latin America Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 77 Brazil Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 78 Brazil Cancer Immunotherapy Market, By Application 2018 - 2030 (USD Million)
Table 79 Brazil Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 Brazil Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 81 Mexico Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 82 Mexico Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 83 Mexico Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 84 Mexico Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 85 Argentina Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 86 Argentina Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 87 Argentina Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 Argentina Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 89 Middle East & Africa Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 90 Middle East & Africa Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 91 Middle East & Africa Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 92 Middle East and Africa Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Middle East and Africa Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 94 Saudi Arabia Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 95 Saudi Arabia Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 96 Saudi Arabia Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 97 Saudi Arabia Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 98 South Africa Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 99 South Africa Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 100 South Africa Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 101 South Africa Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 102 UAE Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 103 UAE Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 104 UAE Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 105 UAE Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Leading market players anticipated to witness highest growth
Table 4 Global Cancer Immunotherapy Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 6 Global Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 7 Global Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Global Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 9 North America Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 10 North America Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 11 North America Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 12 North America Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 13 North America Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 14 U.S. Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 15 U.S. Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 16 U.S. Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 U.S. Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 18 Canada Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 19 Canada Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 20 Canada Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 Canada Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 22 Europe Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 23 Europe Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 24 Europe Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 25 Europe Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Europe Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 27 Germany Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 28 Germany Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 29 Germany Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Germany Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 31 UK Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 32 UK Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 33 UK Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 UK Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 35 France Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 36 France Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 37 France Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 France Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 39 Italy Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 40 Italy Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 41 Italy Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 42 Italy Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 43 Spain Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 44 Spain Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 45 Spain Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 Spain Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 52 Japan Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 53 Japan Cancer Immunotherapy Market, By Application 2018 - 2030 (USD Million)
Table 54 Japan Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Japan Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 56 China Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 57 China Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 58 China Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 59 China Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 60 India Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 61 India Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 62 India Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 63 India Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 64 Australia Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 65 Australia Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 66 Australia Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Australia Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 68 South Korea Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 69 South Korea Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 70 South Korea Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 71 South Korea Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 72 Latin America Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 73 Latin America Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 74 Latin America Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 75 Latin America Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Latin America Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 77 Brazil Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 78 Brazil Cancer Immunotherapy Market, By Application 2018 - 2030 (USD Million)
Table 79 Brazil Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 80 Brazil Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 81 Mexico Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 82 Mexico Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 83 Mexico Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 84 Mexico Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 85 Argentina Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 86 Argentina Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 87 Argentina Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 Argentina Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 89 Middle East & Africa Cancer Immunotherapy Market, By Country, 2018 - 2030 (USD Million)
Table 90 Middle East & Africa Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 91 Middle East & Africa Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 92 Middle East and Africa Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Middle East and Africa Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 94 Saudi Arabia Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 95 Saudi Arabia Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 96 Saudi Arabia Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 97 Saudi Arabia Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 98 South Africa Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 99 South Africa Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 100 South Africa Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 101 South Africa Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
Table 102 UAE Cancer Immunotherapy Market, By Product, 2018 - 2030 (USD Million)
Table 103 UAE Cancer Immunotherapy Market, By Application, 2018 - 2030 (USD Million)
Table 104 UAE Cancer Immunotherapy Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 105 UAE Cancer Immunotherapy Market, By End-use, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Cancer immunotherapy market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2020)
Fig. 10 Strategy framework
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Cancer immunotherapy market: Product movement analysis
Fig. 17 Cancer immunotherapy market: Product segment dashboard
Fig. 18 Cancer immunotherapy market, Product outlook: Key takeaways
Fig. 19 Monoclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 20 Immunomodulators market, 2018 - 2030 (USD Million)
Fig. 21 Oncolytic viral therapies and cancer vaccines market, 2018 - 2030 (USD Million)
Fig. 22 Cancer immunotherapy market: Application movement analysis
Fig. 23 Cancer immunotherapy market: Application segment dashboard
Fig. 24 Cancer immunotherapy market, Application outlook: Key takeaways
Fig. 25 Lung cancer market, 2018 - 2030 (USD Million)
Fig. 26 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 27 Colorectal cancer market, 2018 - 2030 (USD Million)
Fig. 28 Melanoma market, 2018 - 2030 (USD Million)
Fig. 29 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer market, 2018 - 2030 (USD Million)
Fig. 31 Ovarian cancer market, 2018 - 2030 (USD Million)
Fig. 32 Pancreatic cancer market, 2018 - 2030 (USD Million)
Fig. 33 Others market, 2018 - 2030 (USD Million)
Fig. 34 Cancer immunotherapy market: Distribution Channel movement analysis
Fig. 35 Cancer immunotherapy market: Distribution Channel segment dashboard
Fig. 36 Cancer immunotherapy market, Distribution Channel outlook: Key takeaways
Fig. 37 Hospital pharmacy market, 2018 - 2030 (USD Million)
Fig. 38 Retail pharmacy market, 2018 - 2030 (USD Million)
Fig. 39 Online pharmacy market, 2018 - 2030 (USD Million)
Fig. 40 Cancer immunotherapy market: End-use movement analysis
Fig. 41 Cancer immunotherapy market: End-use segment dashboard
Fig. 42 Cancer immunotherapy market, End-use outlook: Key takeaways
Fig. 43 Hospital & clinics market, 2018 - 2030 (USD Million)
Fig. 44 Cancer research centres market, 2018 - 2030 (USD Million)
Fig. 45 Other vaccines market, 2018 - 2030 (USD Million)
Fig. 46 Regional outlook, 2021 & 2030
Fig. 47 Regional market dashboard
Fig. 48 Regional market place: Key takeaways
Fig. 49 North America, SWOT
Fig. 50 Europe, SWOT
Fig. 51 Asia Pacific, SWOT
Fig. 52 Latin America, SWOT
Fig. 53 Middle East and Africa, SWOT
Fig. 54 North America
Fig. 55 North America cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 56 U.S.
Fig. 57 U.S. cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 58 Canada
Fig. 59 Canada cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 60 Europe
Fig. 61 Europe cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 62 UK.
Fig. 63 UK cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 64 Germany
Fig. 65 Germany cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 66 Spain
Fig. 67 Spain cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 68 France
Fig. 69 France cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 70 Italy
Fig. 71 Italy cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific
Fig. 73 Asia Pacific cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 74 Japan
Fig. 75 Japan cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 76 China
Fig. 77 China cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 78 India
Fig. 79 India cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 80 South Korea
Fig. 81 South Korea cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 82 Australia
Fig. 83 Australia cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 84 Latin America
Fig. 85 Latin America cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 86 Brazil
Fig. 87 Brazil cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 88 Mexico
Fig. 89 Mexico cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 90 Argentina
Fig. 91 Argentina cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 92 Middle East and Africa
Fig. 93 MEA cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 94 South Africa
Fig. 95 South Africa cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 96 Saudi Arabia
Fig. 97 Saudi Arabia cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 98 UAE
Fig. 99 UAE cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 100 Ansoff Matrix
Fig. 101 Heat map analysis
Fig. 102 Market differentiators
Fig. 1 Cancer immunotherapy market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2020)
Fig. 10 Strategy framework
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Cancer immunotherapy market: Product movement analysis
Fig. 17 Cancer immunotherapy market: Product segment dashboard
Fig. 18 Cancer immunotherapy market, Product outlook: Key takeaways
Fig. 19 Monoclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 20 Immunomodulators market, 2018 - 2030 (USD Million)
Fig. 21 Oncolytic viral therapies and cancer vaccines market, 2018 - 2030 (USD Million)
Fig. 22 Cancer immunotherapy market: Application movement analysis
Fig. 23 Cancer immunotherapy market: Application segment dashboard
Fig. 24 Cancer immunotherapy market, Application outlook: Key takeaways
Fig. 25 Lung cancer market, 2018 - 2030 (USD Million)
Fig. 26 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 27 Colorectal cancer market, 2018 - 2030 (USD Million)
Fig. 28 Melanoma market, 2018 - 2030 (USD Million)
Fig. 29 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer market, 2018 - 2030 (USD Million)
Fig. 31 Ovarian cancer market, 2018 - 2030 (USD Million)
Fig. 32 Pancreatic cancer market, 2018 - 2030 (USD Million)
Fig. 33 Others market, 2018 - 2030 (USD Million)
Fig. 34 Cancer immunotherapy market: Distribution Channel movement analysis
Fig. 35 Cancer immunotherapy market: Distribution Channel segment dashboard
Fig. 36 Cancer immunotherapy market, Distribution Channel outlook: Key takeaways
Fig. 37 Hospital pharmacy market, 2018 - 2030 (USD Million)
Fig. 38 Retail pharmacy market, 2018 - 2030 (USD Million)
Fig. 39 Online pharmacy market, 2018 - 2030 (USD Million)
Fig. 40 Cancer immunotherapy market: End-use movement analysis
Fig. 41 Cancer immunotherapy market: End-use segment dashboard
Fig. 42 Cancer immunotherapy market, End-use outlook: Key takeaways
Fig. 43 Hospital & clinics market, 2018 - 2030 (USD Million)
Fig. 44 Cancer research centres market, 2018 - 2030 (USD Million)
Fig. 45 Other vaccines market, 2018 - 2030 (USD Million)
Fig. 46 Regional outlook, 2021 & 2030
Fig. 47 Regional market dashboard
Fig. 48 Regional market place: Key takeaways
Fig. 49 North America, SWOT
Fig. 50 Europe, SWOT
Fig. 51 Asia Pacific, SWOT
Fig. 52 Latin America, SWOT
Fig. 53 Middle East and Africa, SWOT
Fig. 54 North America
Fig. 55 North America cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 56 U.S.
Fig. 57 U.S. cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 58 Canada
Fig. 59 Canada cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 60 Europe
Fig. 61 Europe cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 62 UK.
Fig. 63 UK cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 64 Germany
Fig. 65 Germany cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 66 Spain
Fig. 67 Spain cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 68 France
Fig. 69 France cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 70 Italy
Fig. 71 Italy cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific
Fig. 73 Asia Pacific cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 74 Japan
Fig. 75 Japan cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 76 China
Fig. 77 China cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 78 India
Fig. 79 India cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 80 South Korea
Fig. 81 South Korea cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 82 Australia
Fig. 83 Australia cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 84 Latin America
Fig. 85 Latin America cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 86 Brazil
Fig. 87 Brazil cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 88 Mexico
Fig. 89 Mexico cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 90 Argentina
Fig. 91 Argentina cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 92 Middle East and Africa
Fig. 93 MEA cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 94 South Africa
Fig. 95 South Africa cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 96 Saudi Arabia
Fig. 97 Saudi Arabia cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 98 UAE
Fig. 99 UAE cancer immunotherapy market, 2018 - 2030 (USD Million)
Fig. 100 Ansoff Matrix
Fig. 101 Heat map analysis
Fig. 102 Market differentiators
